Bergen, Norway, 6 March 2021?- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, today delivered a Science Spotlight oral presentation
on preclinical COVID-19 data at the annual Conference on Retroviruses and
Opportunistic Infections (CROI), taking place from 6-10 March 2021.

The presentation was led by BerGenBio's collaborator, Professor Wendy Maury,
Professor of Microbiology and Immunology at the University of Iowa (Iowa City,
USA), who presented data showing that AXL enhances the ability of SARS-CoV-2 to
infect cell lines from the human airway, increasing the amount of virus measured
in those cells. Treating the human cell lines, Vero E6 and human ACE2-expressing
A549 lung cancer cell lines, with the AXL kinase inhibitor, bemcentinib reduces
the amount of SARS-CoV-2 virus infecting these cells, and it does this by
reducing ACE2-mediated viral cell entry by endocytosis, rather than at the cell
surface.

Additionally an in vivo study also measured the effect of bemcentinib to treat a
type of coronavirus which naturally infects mice - murine hepatitis virus (MHV).
In this study, not only was bemcentinib found to significantly inhibit the viral
load of MHV found in the liver of these animals, but it also significantly
enhanced signatures of a type I IFN response, a potent mediator of the innate
antiviral response.

In conclusion, the effect of bemcentinib demonstrated potent antiviral effects
in preclinical SARS-CoV-2 and other coronavirus models. Further, the findings
support BerGenBio's ongoing Phase II trial evaluating bemcentinib for the
treatment of hospitalised COVID-19 patients in South Africa and India.

The presentation will be made available on BerGenBio's website under
'Presentations'.

Full details of the presentation are as follows:

Title: Targeting the receptor AXL by bemcentinib prevents SARS-CoV-2 infection

Author: Professor Wendy Maury, Professor of Microbiology and Immunology at the
University of Iowa (Iowa City, USA)

Abstract No. 2672

-Ends-

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases.

In COVID-19, AXL has two synergistic mechanisms of action, it acts a co-receptor
to ACE2, to which the spike protein of the Sars-Cov-2 virus attaches and enters
the host cell, and AXL expression is upregulated that leads to suppression of
the Type 1 Interferon immune response by host cells and in their environment.
Research data confirms bemcentinib inhibits SARS-CoV-2 host cell entry and
promotes the anti-viral Type I interferon response.

In cancer, increase in AXL expression has been linked to key mechanisms of drug
resistance and immune escape by tumour cells, leading to aggressive metastatic
cancers. AXL suppresses the body's immune response to tumours and drives
treatment failure across many cancers. High AXL expression defines a very poor
prognosis subgroup in most cancers. AXL inhibitors, such as bemcentinib,
therefore, have potential high value as monotherapy and as the cornerstone of
cancer combination therapy, addressing significant unmet medical needs and
multiple high-value market opportunities. Research has also shown that AXL
mediates other aggressive diseases including fibrosis.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potentially first-in-class
selective AXL inhibitor in a broad phase II clinical development programme.
Ongoing clinical trials are investigating bemcentinib in multiple solid and
haematological tumours, in combination with current and emerging therapies
(including immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular catalytic
kinase domain of AXL receptor tyrosine kinase and inhibits its activity.
Increase in AXL function has been linked to key mechanisms of drug resistance
and immune escape by tumour cells, leading to aggressive metastatic cancers.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL
antibody, tilvestamab, is undergoing phase I clinical testing. In
parallel, BerGenBio is developing a companion diagnostic test to identify
patient populations most likely to benefit from AXL inhibition: this is expected
to facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Contacts

ir@bergenbio.com

Richard Godfrey CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements


This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.